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Abstract Genetic variations in the myeloid immune receptor TREM2 are linked to several
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neurodegenerative diseases. To determine how TREM2 variants contribute to these diseases, we
performed structural and functional studies of wild-type and variant proteins. Our 3.1 Å TREM2
crystal structure revealed that mutations found in Nasu-Hakola disease are buried whereas
Alzheimer’s disease risk variants are found on the surface, suggesting that these mutations have
distinct effects on TREM2 function. Biophysical and cellular methods indicate that Nasu-Hakola
mutations impact protein stability and decrease folded TREM2 surface expression, whereas
Alzheimer’s risk variants impact binding to a TREM2 ligand. Additionally, the Alzheimer’s risk
variants appear to epitope map a functional surface on TREM2 that is unique within the larger
TREM family. These findings provide a guide to structural and functional differences among genetic
variants of TREM2, indicating that therapies targeting the TREM2 pathway should be tailored to
these genetic and functional differences with patient-specific medicine approaches for
neurodegenerative disorders.
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The precise molecular determinants and mechanisms underlying neurodegenerative diseases remain
uncertain, but recent large-scale genetic sequencing projects have uncovered new candidates associated with these diseases. For example, whole genome and whole exome sequencing has identified
point mutations in the gene encoding the protein TREM2 (triggering receptor expressed on myeloid
cells 2) that correlate with a significantly increased risk of developing Alzheimer’s disease (AD)
(Guerreiro et al., 2013b; Jonsson et al., 2013). In particular, the TREM2 R47H variant is associated
with a risk that is similar to that associated with APOE4, previously the only well-established risk factor for late-onset AD. This mutation correlates with increased cerebrospinal fluid (CSF) tau levels, a
well-established risk factor for AD (Cruchaga et al., 2013), and subsequent studies have identified
this mutation in patients who have frontal temporal dementia (FTD), Parkinson’s disease (PD)
(Rayaprolu et al., 2013), and sporadic amyotrophic lateral sclerosis (ALS) (Cady et al., 2014). A
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eLife digest Alzheimer’s disease is a neurodegenerative disease and the most common cause of
dementia – characterized by memory loss and difficulties with thinking, problem solving and
language – in the elderly. Individuals with rare mutations in the gene that encodes a protein called
TREM2 have a substantial risk of developing Alzheimer’s disease in their mid-60s. A different set of
mutations in the gene for TREM2 can cause a more severe degenerative brain disease known as
Nasu-Hakola disease in much younger people.
Proteins are made up of chains of building blocks called amino acids that need to fold into
specific three-dimensional shapes to allow the protein to work properly. TREM2 is a signaling
protein that is found on the surface of immune cells in the brain. Mutations causing Alzheimer’s and
Nasu-Hakola disease result in the production of mutant TREM2 proteins that differ from the normal
protein by only a single amino acid. It is not clear how different mutations affecting the same protein
can give rise to two distinct neurodegenerative diseases.
To address this question, Kober et al. used a range of techniques to study normal and mutant
TREM2 proteins. First, a technique called X-ray crystallography – which makes it possible to
construct three-dimensional models of proteins – revealed that the mutations responsible for NasuHakola disease are buried deep within the core of the folded TREM2 protein. On the other hand,
mutations associated with Alzheimer’s disease lie on the surface of the protein.
Further experiments examined how these mutations alter the properties of TREM2, revealing that
mutations linked to Nasu-Hakola disease affect the ability of TREM2 to fold correctly and how stable
its final shape is. This results in fewer TREM2 proteins being present on the surface of immune cells.
In contrast, mutations associated with Alzheimer’s disease make it harder for TREM2 to bind to
molecules known as glycosaminoglycans. The Alzheimer’s mutations affect a specific part of TREM2
that is not found in other closely related proteins.
The findings of Kober et al. suggest that TREM2 binding to glycosaminoglycans is likely to be
important in preventing Alzheimer’s disease. The next step following on from this work is to find out
exactly how these interactions affect immune cells, which may aid the development of new therapies
for this disease.
DOI: 10.7554/eLife.20391.002

recent study of more than 1,600 late-onset AD (LOAD) and cognitively normal brains revealed that
microglia-specific networks, including those containing TREM2, are those most significantly dysregulated in LOAD (Zhang et al., 2013). Thus, even in the absence of rare variants in TREM2 that
increase AD risk, TREM2-containing pathways play a significant role in disease. Recent studies in AD
mouse models that are deficient in TREM2 confirm that loss of TREM2 function contributes to classic
AD pathology and demonstrates a crucial role for TREM2 in central nervous system (CNS) biology
(Jay et al., 2015; Wang et al., 2015; Ulrich et al., 2014). TREM2-deficient AD mice display fewer
activated microglia, and the absence of TREM2 prevents microglia proliferation and promotes microglia apoptosis, which was correlated with increased accumulation of Ab plaques (Wang et al., 2015;
Jay et al., 2015). Microglia in TREM2-deficient AD mice displayed less activation and did not engulf
Ab plaques. This impacts the density of Ab plaques and promotes diffuse Ab structures, which in
turn are more neurotoxic, and contributes to the accumulation of classic AD pathology (Wang et al.,
2016; Yuan et al., 2016). These findings highlight a crucial role for TREM2 in maintaining CNS
homeostasis. Therefore,understanding how these risk variants affect TREM2 function and contribute
to the pathogenesis of neurodegenerative diseases is vital to the development of therapies targeting these devastating conditions.
TREM2 is an innate immune receptor expressed on dendritic cells (DCs), resident macrophages
such as osteoclasts and microglia, infiltrating (Jay et al., 2015) and inflammatory (Wu et al., 2015)
macrophages, and CSF monocytes (Colonna and Wang, 2016). It is a type one receptor protein
consisting of an extracellular V-type Ig domain, a short stalk, a transmembrane domain that associates with the adaptor protein DAP12 for signaling, and a cytoplasmic tail (Figure 1a)
(Colonna, 2003). TREM2 has historically been shown to play an anti-inflammatory role in vitro by
antagonizing the production of inflammatory cytokines from bone-marrow-derived macrophages
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Figure 1. Crystal structure of the human TREM2 ectodomain. (a) Schematic of TREM2 cell-surface association with adapter protein DAP12,
which contains an Immuno Tyrosine Activation Motif (ITAM). Engagement of TREM2-L by the ectodomain of TREM2 induces signaling. Domain
boundaries are indicated. (b) TREM2 ectodomain in two orientations with disease-linked residues shown as sticks. The positions of AD risk variants are
shown in magenta, whereas Nasu-Hakola disease (NHD) mutations are shown in cyan. The N-acetylglucosamine (NAG) is shown as green sticks. (c)
Table of TREM2 disease-linked mutations, associated disease, and calculated solvent accessible surface exposure for the side-chain (calculated using
Naccess), along with statistical correlations to AD (OR = odds ratio; MAF = mean allele frequency) (from Jin et al., 2014). Table is highlighted with
same color scheme as Figure 1b. Validated AD risk variants (R47H and R62H) are not marked. Potential AD risk variants are denoted with an asterisk.
(d) Side-by-side stereo view of difference electron density (2mFo-DFc contoured at 2s) for the N79-NAG. (e–g) Difference electron density (2mFo-DFc
contoured at 2s) for the surface-exposed AD-associated mutation positions (e) R47, (f) R62 and (g) T96.
DOI: 10.7554/eLife.20391.003
The following figure supplements are available for figure 1:
Figure supplement 1. Analysis of TREM2 glycosylation, comparison of TREM2 monomers in the crystal structure, and SA-omit maps of AD-linked
residues.
DOI: 10.7554/eLife.20391.004
Figure supplement 2. Packing neighbors for the TREM2 AD risk variant R47 and the TREM2 NHD mutants Y38, T66, and V126.
DOI: 10.7554/eLife.20391.005

(BMDMs) and dendritic cells (BMDDCs) in response to FcR (Hamerman et al., 2006) and Tlr signaling (Turnbull et al., 2006; Ito and Hamerman, 2012). Likewise, TREM2 participates in phagocytosis
of apoptotic cells in cultured microglia and reduces the production of inflammatory cytokines
(Takahashi et al., 2005). However, TREM2-expressing macrophages can also promote inflammatory
disease in the brain (Jay et al., 2015) and lung (Wu et al., 2015). The identity of a physiologic
TREM2 ligand (TREM2-L) remains uncertain, although several classes of molecules have been
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proposed, including bacterial carbohydrates (Daws et al., 2003; Quan et al., 2008), sulfoglycolipids
(Phongsisay et al., 2015), nucleic acids (Kawabori et al., 2015), phospholipids (Cannon et al.,
2012; Wang et al., 2015) and proteins (Stefano et al., 2009; Takegahara et al., 2006; Yoon et al.,
2012; Atagi et al., 2015; Bailey et al., 2015). Additionally, previous studies have identified cells
that express a TREM2-L, including astrocytes (Daws et al., 2003), DCs (Ito and Hamerman, 2012),
BMDMs (Hamerman et al., 2006), neurons and apoptotic cells (Hsieh et al., 2009). This growing
body of literature underscores the case for immune deregulation, specifically involving TREM2-associated pathways in neurodegenerative and inflammatory diseases (Golde et al., 2013).
Intriguingly, genetic variations in TREM2 are associated with two distinct groups of neurodegenerative diseases. Homozygous mutations including early-stop codons (Paloneva et al., 2003;
Soragna et al., 2003), splice site mutations (Numasawa et al., 2011; Chouery et al., 2008),
the coding stalk mutations D134G and K186N (Paloneva et al., 2002), and the coding ectodomain
mutations Y38C, T66M, and V126G (Guerreiro et al., 2013a, 2013c; Le Ber et al., 2014) cause
either NHD, characterized by early-onset dementia, demyelination, and bone cyst lipoma
(Paloneva et al., 2002; Colonna, 2003), or a frontotemporal dementia variant with severe loss of
brain matter but lacking the bone manifestations. By contrast, TREM2 mutations associated with AD
contribute to disease risk as heterozygous variants. In addition to R47H, the coding mutation R62H
is associated with increased risk of AD in independent studies (Jin et al., 2014; Ridge et al., 2016).
These two variants have the strongest risk link to AD. N68K and D87N have also been identified in
AD patients, but because these mutations are very rare, their risk remains uncertain
(Guerreiro et al., 2013b; Jonsson et al., 2013). In addition, the mutation T96K has been linked to a
decreased risk of AD, but this mutation is also too rare to allow verification of this observation
(Jin et al., 2014). This curious segregation of disease phenotypes by distinct mutations occurring
within the same protein suggest that these mutations should have divergent effects on the structure
and function of TREM2.
In order to understand the molecular basis of how different mutations within TREM2 can lead to
distinct neurodegenerative diseases, we performed structural, biophysical, and functional studies of
wild-type (WT) and mutant TREM2 proteins. To facilitate these studies, we developed a novel mammalian expression system to produce the natively folded and glycosylated TREM2 ectodomains in
milligram quantities (Kober et al., 2014, 2015). We determined the crystal structure of the TREM2
ectodomain at 3.1 Å resolution and found that the disease-linked mutations exhibit distinct structural
patterns, suggesting that they would impact TREM2 function through alternate mechanisms. To
investigate this hypothesis, we carried out extensive biophysical, cellular, and functional assays. We
found that NHD-causing mutations impact TREM2 protein folding and stability, whereas AD risk variants decrease binding to the cellular TREM2-ligand (TREM2-L). Furthermore, these AD-linked mutations appear to epitope map a disease-relevant functional surface on TREM2 that facilitates binding
to cell-surface TREM2-L. These findings demonstrate two distinct loss-of-function mechanisms for
TREM2, illuminate a disease-relevant functional surface on TREM2, and pave the way for the development of patient-specific molecular therapies for the treatment of distinct neurodegenerative
diseases.

Results
Structure of the hTREM2 ectodomain
We previously reported the crystallization of the WT human TREM2 ectodomain (amino acids 19–
134) purified from a mammalian cell expression system (Kober et al., 2014). These crystals diffracted to 3.1 Å (Table 1 and Table 2). The TREM2 ectodomain is a V-type Ig domain containing
two disulfide bonds, the canonical Ig disulfide between residues C36 and C110 (bB–bF) and an additional linkage between C51 and C60 (bC-bC’) (Figure 1b). A single N-acetylglucosamine (NAG) glycan that remains after Endo Hf treatment (Figure 1—figure supplement 1a) is clearly visible in the
electron density at residue N79 (Figure 1d and Figure 1—figure supplement 1g). The nine bstrands characteristic of proteins within this Ig domain class are present, and two short a-helix passages are observed spanning b-sheets B–C and E–F. The asymmetric unit (ASU) contains two monomers of hTREM2 in a parallel arrangement, but the limited buried surface area (~400 Å2) and
chemical nature of the interface suggest that this dimer would not exist in solution (Figure 1—figure
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Table 1. Determination of resolution cut-off by evaluation of meaningful data.
To evaluate the functional resolution of data past 3.3 Å, data were scaled to 3.0 Å resolution. Data were successively truncated at 0.1
Å intervals from 3.4 Å to 3.0 Å and the initial 3.3 Å solution was used to initiate molecular replacement, rigid body refinement and XYZ
refinement in PHENIX without manual refinements. After refinement at the higher resolution, the resulting model was used to calculate
R and Rfree values at the immediate lower resolution. If this resulted in a better model, as judged by Rfree, the higher resolution data
are useful for improving the model. Data at resolutions that improved the model are highlighted in green while data at resolutions
that worsened the model are highlighted in red.
Refine at:

Calculate at:

3.3

3.3

3.2

26.26/31.66

25.30/31.47

3.2

26.75/31.88

3.1

3.1

3.0

26.79/31.80
27.71/32.47

27.64/32.87

3.0

28.30/32.52

DOI: 10.7554/eLife.20391.006

supplement 1b). Furthermore, these two monomers are quite similar (Ca RMSD of 0.65 Å, Figure 1—figure supplement 1c), therefore, our analysis of hTREM2 described henceforth will refer to
chain A.

Table 2. Data collection and refinement statistics.
Human TREM2 ectodomain
Data collection
Space group

P 64 2 2

Cell dimensions
a, b, c (Å)

125.76, 125.76, 183.70

a, b, g (˚)

90, 90, 120

Resolution (Å)

50.00–3.10 (3.21–3.10)*

Rsym

0.11 (1.00)

Mean I / sI

21.0 (1.76)

Completeness (%)

99.88 (99.75)

Redundancy

12.9 (13.4)

Refinement
Resolution (Å)

50.00–3.10

No. reflections

16,285

Rwork / Rfree

0.2605/0.2736

No. atoms

1,784

Protein

1,756

Carbohydrate

28

B-factors

93.48

Protein

92.39

Carbohydrate

162.1

R.m.s. deviations
Bond lengths (Å)

0.006

Bond angles (˚)

1.18

*Values in parentheses are for highest-resolution shell.
DOI: 10.7554/eLife.20391.007
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We analyzed the structure to map the location of disease-linked point mutations and noticed an
intriguing pattern. The side chains of mutations causing NHD (Y38, T66 and V126) are all buried
within the core of the Ig fold, whereas the side chains of verified AD risk variants (R47H and R62H)
and possible AD risk variants (N68K, D87N and T96K) all lie on the protein surface (Figure 1b).
Quantification using solvent-accessible surface calculations verified this qualitative observation
(Figure 1c). Using structural analysis, we can hypothesize how the buried NHD mutations could negatively impact protein folding. Y38 is adjacent to C36, which forms an intramolecular disulfide with
C110, so the Y38C mutation most likely disrupts correct disulfide formation (Figure 1—figure supplement 2b). T66 immediately follows the C’ b-sheet and is tightly packed inside the core of the protein, with the side chain hydroxyl engaging the backbone amide of K48 (Figure 1—figure
supplement 2c). The T66M mutation would sterically disrupt this packing and probably destabilize
the protein. V126 is located on b-sheet G; it is entirely buried and contributes to a hydrophobic core
of the buried residues F24, D104, A105, and Y108. Removal of the side chain by the V126G mutation
would disrupt this packing and probably destabilize this hydrophobic core (Figure 1—figure supplement 2d). In addition, sequence analysis reveals that Y38 and V126 are conserved within the TREM
family, implying that they are probably required to preserve the common fold within this family of
receptors (Figure 5c). The T66 residue is less conserved in the TREM family, but is highly conserved
in TREM2 proteins across species.
In stark contrast to the NHD mutants, all of the residues implicated in the development of AD are
surface exposed (Figure 1b,c,e–g) and engage in very few structure-stabilizing contacts. R47, the
residue with the strongest link to AD as the R47H variant, is at the end of the loop preceding b-sheet
C. It is well-ordered in the structure with the side chain lying parallel along the surface of the protein,
and the side-chain amines engage the carbonyl oxygen of T66 (Figure 1e, Figure 1—figure supplement 2d, and Figure 1—figure supplement 2a). R62, another strong AD risk factor as the R62H variant, comes after the loop marked by the C51-C60 disulfide bond (Figure 1f and Figure 1—figure
supplement 2e). Its side chain faces outward and makes no polar contacts. N68 is also surface
exposed and its side chain makes no obvious polar contacts within the molecule. D87 is at the end
of b-strand D; its side chain extends from the protein surface and the side-chain carboxyl engages
the backbone amide of G90. This interaction probably stabilizes the bD-E loop. T96 is on the end of
b-strand E and its side chain points away from the surface and engages the side chain of Q33
(Figure 1g and Figure 1—figure supplement 2f). On the basis of this structural analysis of neurodegenerative disease mutations in TREM2, we hypothesized that NHD mutants (which are buried)
would affect protein folding and stability and thus decrease their surface expression, whereas AD
risk variants (which lie on the protein surface) would not affect surface expression and instead probably impact ligand binding.

Impact of TREM2 variants on folding and surface expression
To begin to test tour hypothesis, we expressed each TREM2 ectodomain variant and analyzed their
secretion and solution properties using size exclusion chromatography. WT hTREM2 ectodomain
consistently eluted as a monomer (Figure 2a and b), in accordance with our crystallographic analysis.
The verified (R47H and R62H) and possible (N68K, D87N and T96K) AD-risk variants all elute at the
same volume as WT TREM2 (Figure 2—figure supplement 1g–l), suggesting that these mutations
do not drastically alter the folding or oligomerization of TREM2 in solution. Furthermore, all of the
TREM2 AD risk variant ectodomains migrated as monomers in the absence of reducing agent
(Figure 2b). By contrast, although the buried NHD mutants Y38C, T66M, and V126G were secreted,
they elute much earlier, consistent with aggregation and misfolding of these proteins (Figure 2—figure supplement 1m–o). Consistent with this observation, SDS-PAGE analysis of TREM2 NHD
mutants in the absence of reducing agent showed that these ectodomains were largely produced as
covalent dimers or trimers, indicating that misfolding of these mutants promoted the formation of
aberrant intermolecular disulfide bonds (Figure 2c).
Given that our structural analysis suggested that the TREM2 NHD mutants should be misfolded,
we were surprised to observe that these ectodomains bypassed cellular quality control and were
secreted. We therefore devised an assay using flow cytometry to investigate whether these point
mutants in full-length TREM2 impair cell surface expression. DAP12 was co-expressed with FLAGtagged WT or mutant TREM2 full-length proteins and surface expression was measured either by an
anti-FLAG antibody or by anti-TREM2 sera raised against our secreted, folded protein. Whole-cell
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Figure 2. Chromatographic and surface expression analysis of WT and variant TREM2. The schematic depicts the domain of TREM2 used in the
experiments shown in (a–c). (a) Gel filtration chromatography profile (Superdex 200 10/300 GL) of purified WT human TREM2 ectodomain showing
a single monomeric peak. (b) SDS-PAGE analysis of purified TREM2 AD risk variants prepared with (+) and without (-) reducing agent (bmercaptoethanol). (c) Western blot analysis of TREM2 NHD mutants secreted from transfected 293F cells prepared with (+) and without (-) reducing
agent (b-mercaptoethanol). The NHD mutants Y38C, T66M, and V126G all migrate as higher MW oligomers under non-reduced conditions, indicating
that they are misfolded and linked by aberrant intermolecular disulfide bonds. Purified WT TREM2 is shown for comparison. Representative of more
than three independent expressions. The second schematic depicts FLAG TREM2 used in the experiments shown in (d–h). (d–e) Surface expression of
Figure 2 continued on next page
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Figure 2 continued
WT and variant TREM2 in 293F cells assayed by flow cytometry. Full-length FLAG-WT or mutant TREM2 were co-transfected with mDAP12 into 293F
cells. Surface expression was measured by either (d) a polyclonal serum or (e) an anti-FLAG antibody. Normalized TREM2 indicates the normalized
fraction of cells staining positive over DAP12-only background. Data are from four (d) or five (e) independent experiments. Bars are color-coded in the
same way as the residues in Figure 1b (cyan = NHD mutant; magenta = AD risk variant). Error bars are SEM. Significance was determined by ANOVA
with Bonferroni post-test correction. (*p<0.05, **p<0.01, and ***p<0.001). (f) Western blot analysis of whole-cell lysates of 293F cells used in (d) and (e)
showing expression levels of WT, NHD mutant (Y38C, T66M and V126G), and AD risk variant (R47H, R62H, N68K, D87N and T96K) TREM2. Note that
the NHD mutants are more highly expressed than the AD risk variants. (g) Confocal microscopy of 293F cells co-transfected with DAP12 and FLAGTREM2. Cells were fixed and either permeabilized (left) or non-permeabilized (right) and stained with anti-FLAG antibody (red). (h) FLAG-TREM2 fulllength constructs were co-transfected with DAP12 into 293T cells and expression analyzed by anti-FLAG immunoblot. Samples were prepared by
suspending cells in reducing SDS loading buffer and boiling for no more than 5 min. We observe SDS-resistant aggregate bands for the NHD variants,
which were largely absent in WT and AD risk variants. The T96K variant shows some light aggregation, consistent with the slight shift (~5˚C) in
denaturation temperature for that variant (Figure 3). Schematic depicts FLAG TREM2 signaling assay employed in the experiments shown in (i–j). (i)
TREM2 signaling analyzed by phosphor-ERK1/2 and ERK1/2 immunoblot in RAW264.7 macrophage cells transfected with WT or variant FLAG-TREM2.
(RAW264.7 cells express endogenous DAP12.) 24 hr post-transfection, cells were stimulated with anti-FLAG antibody (1:100) for the indicated length of
time. ERK/pERK content was assessed by immunoblot. In these cells, we observe pERK at 10 min post-stimulation. However, only WT sustained
signaling 30 min post-stimulation. (j) TREM2 signaling analyzed in Cos-7 cells as in (c). Cos-7 cells were co-transfected with DAP12 and TREM2. In these
cells, there is a non-specific antibody response at 10 min. However, as in the RAW264.7 cells, we observe sustained WT signaling at the later time point
which is diminished in R47H and Y38C variants.
DOI: 10.7554/eLife.20391.008
The following figure supplements are available for figure 2:
Figure supplement 1. Analysis of WT and variant TREM2 ectodomains by size exclusion chromatography.
DOI: 10.7554/eLife.20391.009
Figure supplement 2. hTREM2 surface expression probed using a commercial antibody.
DOI: 10.7554/eLife.20391.010

expression levels of the TREM2 NHD mutants were slightly higher than those of WT or AD risk variant TREM2 (Figure 2f). However, as predicted by our structural analysis, anti-TREM2 staining was
decreased for the NHD mutants Y38C, T66M, and V126G, but not for the AD risk variants R47H,
R62H, N68K, D87N, and T96K (Figure 2d). Similar observations were made using a commercial antiTREM2 antibody (R&D, Figure 2—figure supplement 2). By contrast, the anti-FLAG antibody
showed surface expression for all TREM2 mutants (Figure 2e). We next examined cells expressing
TREM2 WT, NHD mutant Y38C, and AD risk variant R47H by immuofluorescence confocal microscopy in the presence or absence of permeabilization. We found that the surface expression pattern
in non-permeabilized cells was similar for all cell types, whereas in permeabilized cells, the NHD
mutant Y38C displayed diffuse intracellular accumulation, in comparison to WT and R47H which displayed a distinct punctate staining pattern (Figure 2g). Taken together, these results suggest that
NHD mutant proteins do retain some level of surface expression; but the protein is misfolded or
aggregated and thus is not recognized by conformation-specific TREM2 antibodies. Consistent with
these observations, we found significant amounts of SDS-resistant aggregates by anti-FLAG immunoblotting when expressing the full-length TREM2 NHD mutants in 293T cells (Figure 2h). Finally,
we evaluated how these different classes of mutations impact TREM2 signaling by crosslinking the
different versions of FLAG-TREM2 using anti-FLAG antibody. Consistent with our observation of
FLAG-TREM2 on the cell surface for all the variant proteins, we found that while both the Y38C and
R47H variants have some signaling potential, as assessed by phosphorylated-ERK blotting in
RAW264.7 and Cos-7 cells, neither of these variants sustains signaling as efficiently as WT TREM2
(Figure 2i,j). The loss of sustained signaling by the disease variants may suggest that these
mutant proteins have aberrant folding kinetics (and thus are replenished more slowly at the surface
than WT proteins) or cannot bind co-factors that may be required to sustain signaling. Altogether,
these experiments demonstrate that the buried residue changes linked to NHD cause misfolding
and aggregation, with variable impact on surface expression, as would be suggested by our structural analysis.

AD variants slightly impact TREM2 stability and structure
We next sought to evaluate whether the AD-linked surface mutations affect protein structure or stability using sensitive solution techniques. First, we used circular dichroism (CD) spectroscopy to
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analyze whether AD-linked variants induced large conformational changes in the TREM2 ectodomain. For these experiments, we chose to analyze the R47H and R62H mutations, as they represent
the most significant TREM2 risk factors identified to date, as well as the T96K mutation, which is a
sporadically occurring mutation that is not significantly associated with AD. In order to evaluate
whether the point mutations induced conformational changes, we collected CD spectra on the proteins, analyzed for large changes, and compared the ratio in minima at 214 nm (due to b sheets) to
minima at 233 nm (due to tryptophans), which are characteristic features of the CD spectra for Ig
folds (Sikkink and Ramirez-Alvarado, 2008). We found that R62H and T96K displayed CD spectra
similar to WT proteins while, surprisingly, R47H showed a subtle, yet statistically significant difference in the 214 nm/233 nm ratio (Figure 3a and b). Thus the R47H mutation in TREM2 seems to
induce a small, but measurable, conformational change, whereas the R62H and T96K mutations do
not induce any structural changes detectable by CD.
We next investigated the impact of these mutations on thermal stability using differential scanning fluorimetry (DSF) (Niesen et al., 2007). Each surface variant produced slightly lower denaturation temperatures, with R47H and R62H marginally reduced when compared to WT proteins and
T96K having the lowest denaturation temperatures (Figure 3c). As a control, the same experiments
were carried out in the presence of 1 mM DTT, which induced the expected shift to lower denaturation temperatures by disrupting the disulfide bonds. We also used thermal denaturation CD to
assess the thermal stability of these proteins. By obtaining full CD scans at 5˚C increments, we
observed that TREM2 has a denaturation transition at 225 nm, consistent with other Ig domains

Figure 3. Structure and stability analysis by CD and DSF of human WT and AD-linked surface variant TREM2 ectodomains. (a) CD spectra of human WT
TREM2 (blue) and R47H (red), R62H (brown), and T96K (green) variants. (b) Ratio of CD minima at 214 nm and 233 nm reveals that R47H has an altered
CD spectrum. Minima ratios were measured on five (WT and R47H) or three (R62H and T96K) independent protein preparations, respectively. (c)
Thermal melt temperatures measured by DSF. (d) WT and variant TREM2 thermal denaturation measured by CD at 225 nm while increasing the
temperature from 20˚C to 90˚C with or without 1 mM DTT.
DOI: 10.7554/eLife.20391.011
The following figure supplement is available for figure 3:
Figure supplement 1. Structure and stability analysis by CD and DSF of human WT and AD-linked surface variant TREM2 ectodomains.
DOI: 10.7554/eLife.20391.012
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(Sikkink and Ramirez-Alvarado, 2008), and this wavelength was monitored in subsequent denaturation experiments (Figure 3—figure supplement 1a). WT TREM2 and all the TREM2 variants tested
showed reversible thermal denaturation as they reacquired their native spectra rapidly after cooling
from 90˚C to 20˚C, but their ability to refold was ablated in the presence of DTT (not shown). In contrast to DSF measurements, thermal denaturation by CD did not show a difference between WT,
R47H, and R62H proteins; however, the T96K variant has a pronounced shift towards lower denaturation temperature (Figure 3d). In the presence of DTT, all proteins had lower denaturation temperatures (Figure 3d). We further assayed stability using chemical denaturation by titration of guanidineHCl (GuHCl) in CD experiments. The R47H and R62H proteins melt at slightly lower GuHCl concentrations than the WT protein, while the T96K variant unfolds at lower GuHCl concentrations than
R47H and R62H, consistent with the thermal melt experiments (Figure 3—figure supplement 1b).
Thus, as predicted by our structural analysis, the AD-risk surface variants do not induce large conformational changes in TREM2, nor do they dramatically impact protein stability, but they can induce
subtle changes in both parameters.

TREM2 AD risk variants impact binding to TREM2-L
Our structural analysis suggested that AD risk variants might impact function by altering ligand binding due to the surface presentation of the mutated residues. Recently, TREM2 was shown to signal
following stimulation of reporter cells by plated phospholipids, and the R47H mutation resulted in
loss of signaling (Wang et al., 2015). To test the direct binding of TREM2 to phospholipids in a cellfree system, we used purified protein in solid-state ELISA and liposome sedimentation assays. Consistent with the results of previous work (Cannon et al., 2012), we detected TREM2 binding to phospholipids by both ELISA and liposome sedimentation. However, we did not observe differences in
phospholipid discrimination or in direct lipid binding between WT and AD variant TREM2 ectodomains (Figure 4—figure supplement 1a–c). We therefore investigated binding to a cell surface
ligand (TREM2-L). Although no endogenous protein ligand for TREM2 has yet been identified, several cell types have been reported to express a ligand on the basis of staining with a TREM2-Fc
fusion construct (Ito and Hamerman, 2012; Hamerman et al., 2006; Daws et al., 2003;
Hsieh et al., 2009; Stefano et al., 2009). In order to evaluate the effect of AD-linked mutations on
TREM2 binding to TREM2-L, we constructed a novel TREM2 protein cell-binding reagent containing
a site-specific BirA-biotinylation sequence on the C-terminus of TREM2, which could then be complexed with PE-labeled streptavidin to create a tetrameric cell-staining reagent (Figure 4a). In initial
experiments, we found that both human and mouse TREM2/SA-PE tetramers were able to bind Neuro2A (N2A) and THP-1 cells (Figure 4b–d,f,g and Figure 4—figure supplement 2a,c). To validate
the specificity of our reagent, we cultured THP-1 cells with various immune stimuli and found that
overnight treatment with PMA/ionomycin dramatically decreased binding of TREM2/SA-PE tetramers to THP-1 cells (Figure 4b and c), while the myeloid cell marker CD45 remained unchanged
(not shown). Other stimuli tested (overnight exposure to IL-13, Poly I:C, LPS, or M-CSF) did not alter
staining (Figure 4—figure supplement 2a). PMA/ionomycin treatment is the first identified stimulus
that ablates TREM2 staining, and this confirms that TREM2 recognizes a specific cell-surface ligand.
We next sought to interrogate the endogenous target recognized by TREM2 on the cell surface,
and found that TREM2 binding is sensitive to proteinase treatment of cells prior to incubation with
our staining reagent (Figure 4d and Figure 4—figure supplement 2b). Treatment with proteinase K
abolished binding while the more specific proteases chymotrypsin and elastase had an intermediate
effect. Proteinase K treatment did not affect cell viability, which was >99% by 7-aminoactinomycin D
(7-AAD) staining (Figure 4—figure supplement 2f). This demonstrates that TREM2-L contains a protein component. In addition, given the high pI of TREM2, and the frequent reports of anionic potential ligands for TREM2, we reasoned that proteoglycans containing highly sulfated
glycosaminoglycans (GAGs) may facilitate cell-surface binding. We tested binding to wild-type CHOK1 cells, which express heparan and chondroitin sulfates, and to CHO-745 cells, which are deficient
in GAG maturation and surface expression (Esko et al., 1985). In this experiment, GAG-dependent
cell binding of the TREM2 tetramer was observed (Figure 4e). Next, we used heparinases (which
also cleave heparan sulfates) and chondroitinase ABC to ask whether TREM2 selectively binds either
type of GAG. In CHO (Figure 4e), THP-1 (Figure 4f) and N2A (Figure 4g) cells, treatment with heparinases had a pronounced effect on cell surface binding while chondroitinase only slightly
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Figure 4. AD risk variants in TREM2 alter binding to cell surface TREM2-L. (a) Schematic outlining the flow cytometry experiments in (b–g). TREM2
ectodomains were specifically biotinylated at the C-terminus and probed for binding to TREM2-L on the surface cells, which was reduced by pretreating cells with proteinases or heparinases. (b–c) Flow cytometry analysis of either (b) mTREM2/SA-PE tetramer or (c) hTREM2/SA-PE tetramer
staining of THP-1 cells ± PMA/ionomycin treatment. (d) Flow cytometry analysis of hTREM2/SA-PE tetramer staining of THP-1 cells pretreated by various
proteases. (e) mTREM2 staining of CHO-745 (GAGless) and CHO-K1 cells. CHO-K1 cells were treated with a cocktail of heparinases, chondroitinase
ABC, or both. (f–g) mTREM2 staining of (f) THP-1 and (g) N2A cells treated with heparinases, chondroitinases, or both. (h) Schematic outline of control
cell-binding experiments with the TREM-like proteins TREML2 and TREML4. On the left is a schematic of receptor versions of TREM2, TREML2, and
TREML4, along with calculated pI values for the respective ectodomains. (i) Tetramer staining of TREM family ectodomains to N2A cells. (j) Schematic
outlining monomeric TREM2-6His cell-staining experiments. Cells were stained with monomeric TREM2-6H and detected using PE-labeled anti-6H
antibody. (k) Representative plot of THP-1 staining by hTREM2-6H analyzed by flow cytometry. (l) MFI of anti-6His staining of SEC-purified hTREM2 WT
and variant ectodomains pre-incubated with THP-1 cells at the indicated concentrations. All data are representative of at least two independent
experiments.
DOI: 10.7554/eLife.20391.013
The following figure supplements are available for figure 4:
Figure supplement 1. TREM2 lipid binding as assessed by phospholipid ELISA and liposome sedimentation.
DOI: 10.7554/eLife.20391.014
Figure supplement 2. TREM2 binding to mammalian cells.
DOI: 10.7554/eLife.20391.015
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diminished binding, together implicating GAGs, specifically heparin sulfate, as a major component
of the cell surface TREM2-L.
Next, we tested the impact of TREM2 AD risk variants on TREM2-L binding in three different formats. For these experiments, we chose to compare WT TREM2, the validated TREM2 AD risk variants (R47H and R62H), and the possibly protective AD risk variant (T96K). We utilized anti-6H
detection of purified monomeric hTREM2 ectodomains bound to THP-1 cells (Figure 4j,k, and l), tetramer staining of WT and variant mTREM2 binding to N2A and THP-1 cells (Figure 4—figure supplement 2c,d), and competition assays in which SEC-purified monomers competed with SA-PElabeled WT tetramers (Figure 4—figure supplement 2e). Consistent with our hypothesis, the ADlinked variant R47H displayed markedly diminished binding to N2A and THP-1 cells. In stark contrast, the potentially AD-protective T96K variant significantly increased binding. The R62H variant
reduced binding as measured in the anti-6H format, but the reduction in binding was less
dramatic when measured by competition or tetramer staining, suggesting an intermediate decrease
in affinity. Thus, as suggested by our structural analysis, the AD risk variant R47H TREM2 negatively
impacts binding to cell surface TREM2-L, whereas the variant T96K results in increased cellular binding. These data, together with our direct phospholipid binding experiments, suggest that TREM2
AD-risk variants retain phospholipid binding, and instead impact binding to cell surface GAGs. As
the R47H risk variant is able to bind phospholipids directly, but does not signal in cellular assays of
TREM2 signaling triggered by plated phospholipids (Wang et al., 2015), we suggest that TREM2
interaction with GAGs in cis is likely required to orient or cluster TREM2 to mediate signaling upon
stimulation by phospholipids. Alternatively, phospholipids may function to orient TREM2 on the cell
surface for proper presentation to GAGs and/or additional as of yet undefined protein surface
receptors.

AD risk variants map a unique functional surface on TREM2
Our cell surface TREM2-L binding experiments categorized the naturally occurring TREM2 mutations
as loss-of-binding (R47H and R62H) and enhancement-of-binding (T96K) compared to WT, and
showed that these mutations influence TREM2 interactions with cell surface GAGs. We returned to
analysis of our crystal structure in order to interpret these observations. Upon mapping the electrostatic surface of hTREM2, we noticed a large basic surface that was not present on the surface of
other TREM family receptors for which coordinates are available (mTREM1, PDB 1 U9K,
[Kelker et al., 2004a]; hTREM1, PDB 1SMO, [Kelker et al., 2004b]; and TLT-1, PDB 2FRG
[Gattis et al., 2006]) (Figure 5a,b and d–f). Furthermore, sequence analysis shows that the residues
constituting this basic patch are highly conserved within TREM2, but not within the rest of the TREM
family, suggesting that this interface has evolved specifically toward a role in TREM2 function
(Figure 5c). To demonstrate this, we prepared staining tetramers for other TREM-like family members with similar overall high pI values calculated for the ectodomain (Figure 4h). Consistent with
our hypothesis, TREM2 ectodomain tetramers bound to N2A cells, while tetramers of ectodomains
from TREM-like 2 (TREML2) and TREM-like 4 (TREML4) did not (Figure 4i). This cluster of residues
contains most of the AD-linked surface mutations (including R47H and R62H). Additionally, the T96K
mutation is located adjacent to this basic patch and would therefore extend it, providing a structural
explanation for the gain of function observed with this variant (Figure 5b). To test whether additional basic residues located within this surface influence TREM2-L binding, we selected two other
basic residues that are conserved only in TREM2 (R76 and R77), and assayed the ability of these variants to bind TREM2-L using our flow cytometry assay. We found that both a R76D and a R77D
mutation decreased binding to TREM2-L on THP-1 cells in a manner similar to the validated AD risk
variants (R47H and R62H) (Figure 5g). Together, the data indicate that this surface represents a conserved functional interface on TREM2 that participates in cell-surface ligand binding and that this
surface is unique to TREM2 within the TREM family.

Discussion
Here we elucidate how distinct point mutations in TREM2 give rise to different neurodegenerative
diseases via two separate loss-of-function mechanisms. Our studies indicate, as presaged by our
crystal structure, that NHD-linked mutant residues are buried and impact protein folding and stability, while AD-linked variant residues are on the protein surface and do not diminish the stability or
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Figure 5. AD risk variants reveal a functional surface on TREM2. (a) Electrostatic surface of hTREM2 and (b) hTREM2 rotated 90˚. The extended basic
patch on hTREM2 is outlined with a dashed line. (c) Structure-based sequence alignment of human (h) and mouse (m) TREM family members.
Secondary structure assigned using the DSSP server. Invariant residues are shown in magenta and conserved residues are shown in yellow. Disulfide
bonds are numbered in green. NHD residues are highlighted with black boxes and AD residues in blue boxes. Basic patch residues are labeled with
blue asterisks. (d) mTREM-1 (1 U9K), (e) hTREM-1 (1SMO), and (f) hTLT-1 (2FRG) aligned with hTREM2 as in (a). Electrostatic potential was plotted on
the solvent-accessible surface using the AMBER force field and the PDB2PQR server within the APBS Pymol plugin. Scale is 6.0 kT/e (blue) to +6 kT/e
(red). (g) Flow cytometry analysis of WT, R76D, and R77D hTREM2/SA-PE binding to TREM2-L on THP-1 cells. Representative of two independent
experiments.
DOI: 10.7554/eLife.20391.016

surface expression of the molecule but instead impact ligand engagement (Figure 6a). Several variants have been reported for TREM2, but some are very rare, so it is not clear whether they associate
with AD risk. The structure-based studies presented here provide a framework with which one could
make predictions as to the variant’s impact on function. Our observation of detectable misfolded
cell-surface TREM2 NHD mutant proteins was surprising, given that one would expect that the cellular quality-control machinery should degrade misfolded proteins and prevent their surface expression. In addition, previous reports noted decreased surface expression for these mutants
(Park et al., 2015; Kleinberger et al., 2014). Here, we used an approach that probes surface
expression using both non-conformational (anti-FLAG) and conformational (anti-hTREM2) antibodies.
We found that both the NHD-associated and AD-linked mutant proteins reach the cell surface, however the NHD-associated TREM2 mutants are probably not functional as they are either misfolded or
aggregated, and thus are not recognized by the conformational-dependent antibodies. These results
are supported by our analysis of the solution behavior of theTREM2 ectodomains of these mutant
proteins. An alternative explanation could be that the FLAG tag or overexpression drives the surface
expression of these mutated proteins; but we do not think that is the case since we found that the
TREM2 ectodomains carrying these mutations (which contain a different tag that is on the opposite
terminus) were also secreted. These findings are of potential therapeutic value, as the discovery of
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Figure 6. Models developed from the current data. (a) Current model for the role of TREM2 ectodomain point mutations in neurodegenerative
diseases. WT TREM2 is surface expressed in complex with DAP12 and engages TREM2-L normally. AD risk variants do not impair surface expression,
but do impair ligand binding. They occur heterozygously, so this would lead to overall reduced TREM2 function in individuals carrying these risk
variants. NHD mutations cause misfolding, which leads to aggregation and impaired surface expression. These mutations occur homozygously, leading
to no TREM2 function in individuals carrying these mutations. (b) Current model for the engagement of possible TREM2 ligands investigated here.
Membrane-bound or soluble TREM2 (sTREM2) produced by proteolytic cleavage likely engages GAGs via the basic patch and engages phospholipids
(PL) via the hydrophobic patch. In addition, there is a protein component of TREM2-L.
DOI: 10.7554/eLife.20391.017
The following figure supplement is available for figure 6:
Figure supplement 1. hTREM2 has an extended hydrophobic surface.
DOI: 10.7554/eLife.20391.018

molecular chaperones that rescue the folding of and restore function to these mutants could be pursued for patient-specific NHD treatments.
In contrast to the buried NHD mutant proteins, the AD risk variants lie on the surface of the protein and do not severely impact the protein folding or stability of TREM2. However, it should be
noted that the R47H mutation does induce a subtle change in secondary structure detectable by
CD. The AD mutations probably alter TREM2 function by impairing ligand binding. Recent studies in
AD mouse models that are deficient in TREM2 confirm that loss of TREM2 function contributes to
classic AD pathology and suggest a crucial role for TREM2 in microglia function (Jay et al., 2015;
Wang et al., 2015; Ulrich et al., 2014). TREM2-deficient AD mice display fewer activated microglia,
and the absence of TREM2 prevents microglia proliferation and promotes microglia apoptosis, which
is correlated with increased accumulation of Ab plaques (Wang et al., 2015; Jay et al., 2015).
Microglia in TREM2-deficient AD mice display less activation and do not engulf Ab plaques, which
reduces the density of Ab plaques and promotes diffuse Ab structures, which, in turn, are more
neurotoxic and contribute to the accumulation of classic AD pathology (Wang et al., 2016;
Yuan et al., 2016). These models suggest a crucial role for TREM2 in microglia biology and in the
turnover of Ab. On the basis of the conserved nature of AD-linked basic surface residues and our
analysis of cell-surface ligand binding for multiple cell lines, we favor the concept that AD risk variants lead to impaired binding of TREM2-L, which in turn perturbs microglia function.
With this in mind, we investigated how AD risk variants in TREM2 affect binding to
previously identified and newly hypothesized ligands based on the analysis of ourcrystal structure.
The many diverse ligands reported for TREM2 may in fact suggest that TREM2 is capable of recognizing multiple ligands and that under different conditions, their respective affinities might tune signaling accordingly. For example, low-affinity ligands may induce a tonic inhibitory signal while
ligation of a high-affinity ligand could result in an activating response. Indeed, anionic bacterial carbohydrates (Daws et al., 2003), phospholipids (Wang et al., 2015), myelin lipids (Poliani et al.,
2015), and even purified DNA (Kawabori et al., 2015) all activate TREM2 reporter cell lines. This is
not surprising in light of our crystal structure, which reveals an extended basic patch on the surface
of TREM2 that would be capable of forming electrostatic interactions with these anionic ligands. In
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contrast to highly selective phospholipid binding by other Ig domains (Kobayashi et al., 2007;
Miyanishi et al., 2007; Santiago et al., 2007; Simhadri et al., 2012), purified TREM2 shows only
broad discrimination for anionic (PA, PG, PI, PS) over more neutral (PC, PE) lipids (Figure 4—figure
supplement 1a,b and c). Structurally, Ig domains with selective lipid binding feature a canonical FG
loop motif that contains large hydrophobic residues, absent in TREM2, which mediate membrane
insertion and acyl chain binding (Tietjen et al., 2014) (Figure 4—figure supplement 1d,e). Moreover, while TREM2 does share a conserved aspartic acid residue from this motif, which chelates a
required Ca2+ ion for the TIM and CD300a proteins, TREM2-lipid binding is not sensitive to EDTA,
unlike TIM and CD300 (Figure 4—figure supplement 1e and f). Thus, while we do observe direct
binding of TREM2 to phospholipids, it does not appear that TREM2 binds phospholipids with high
selectivity or using the same binding mode as other phospholipid-binding Ig domains. By contrast, it
should be noted that there is a long and narrow hydrophobic patch on the end of TREM2 most distal
from the plasma membrane (Figure 6—figure supplement 1) that is the most likely lipid-binding
surface. Interestingly this patch is adjacent to the basic patch, which could mediate interaction with
anionic phospholipid head groups (Figure 6b). These hypotheses will need to be tested in future
studies using sensitive binding assays (such as surface plasmon resonance) and crystallographic studies of TREM2-phospholipid recognition. In contrast to recent studies employing reporter cells
expressing TREM2 R47H (Wang et al., 2015), we did not observe any large differences in binding to
phospholipids for any of the validated TREM2 AD risk variants. In light of our experimental observations, we believe this is best explained by the hypothesis that another interaction (such as TREM2
binding to GAGs, which we show here is impacted by these AD risk variants) is required to mediate
phospholipid signaling; thus in the context of cellular experiments, TREM2 R47H shows diminished
signaling, while in direct lipid-binding assays it performs in the same way as WT TREM2. This is
potentially supported by a recent report that TREM2 binds to isolated PS, but does not bind apoptotic Jurkat T cells, which present PS on their cell surface but may also be deficient in GAGs
(Bailey et al., 2015). The results presented here suggest that the point mutations in TREM2 participate in neurodegenerative disease pathogenesis through distinct molecular mechanisms.
We found that the validated AD risk variants in TREM2 impact binding to a cell-surface ligand
(TREM2-L). This ligand does appear to contain a protein component, as pre-treatment of cells with
proteases decreases or prevents the binding of TREM2 to these cells. This interaction also appears
to be highly GAG-mediated, as TREM2 cell-staining tetramers do not bind CHO 745 cells, which do
not express GAGs. This interaction seems most dependent on heparan sulfate, as treatment with
heparin sulfatases remove much of the observed binding. As the AD risk variants most notably
impact binding to TREM2-L, we reason that this interaction is involved in the pathogenesis of AD. In
support of this, we find that the mutations R47H and perhaps R62H deleteriously impact TREM2-L
recognition. By contrast, T96K appears to be a potential gain-of-function mutation in our binding
experiments. Interestingly, this mutation appears at a much higher frequency than R47H and R62H,
and in some studies it has been reported to be enriched in European-American AD cases compared
to controls; overall it is associated with a decreased odds ratio for the development of late-onset AD
(Figure 1c), again suggesting the TREM2-L binding function is coupled to AD risk. Altogether, the
structural and functional analysis of these variants illuminates a surface epitope that is specific to
TREM2, that is not conserved among the other members of the TREM family, and that mediates
binding to a cell-surface ligand. Additional point mutations localized to that surface also resulted in
loss of binding, supporting this functional role. Our results suggest that this ligand may have a specific protein component in addition to GAGs. On that note, while this manuscript was in preparation,
it was reported that TREM2 binds lipid-loaded ApoE and that this interaction facilitates uptake of
Ab loaded into lipoparticles by microglia (Yeh et al., 2016). This report also suggests that TREM2
AD risk variants decrease binding to ApoE, but binding affinities were not quantitated. However, we
do not suspect that ApoE is the protein component of cell surface TREM2-L because it is a soluble
rather than a surface-bound protein. Our study demonstrates that TREM2 can specifically bind
GAGs, utilizing the basic patch; other TREM-like proteins with the same overall calculated pI, but
lacking the basic patch residues, do not bind GAGs. We also demonstrate that TREM2 AD risk variants affect binding to GAGs. Future studies will need to focus on how TREM2 binding to GAGs and
ApoE are coordinated and how they impact TREM2 function in microglia.
Our results illustrate two distinct paths to loss-of-function in TREM2, so how might these different
mechanisms result in either AD or NHD? In attempting to explain this, it is important to take into
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account genetics-based dosage affects (Figure 6a). In NHD, the mutations are homozygous and the
TREM2 is either deleted or misfolded, leading to a complete loss of function, and more serious and
early-onset neurodegenerative disease. In AD, the mutations are heterozygous and impair function
(but do not completely abolish it), leading to less severe and late onset neurodegenerative disease.
Under this hypothesis, it should be possible that a heterozygous NHD mutant would give increased
risk for AD. Consistent with this, there have been reports of rare AD cases containing heterozygous
NHD variants, including Q33X, Y38C, and T66M (Guerreiro et al., 2013b). In addition, TREM2 may
function not only as a receptor but also as a signaling molecule as it can be cleaved. We have
recently shown that the soluble TREM2 may be a survival signal in bone-marrow macrophages
(Wu et al., 2015). Interestingly, we have observed that the absence of TREM2 in an AD mouse
model prevents microglia proliferation and promotes microglia apoptosis, suggesting that soluble
TREM2 could play a similar role in the CNS (Wang et al., 2015). Accordingly, soluble TREM2 can be
detected in the CNS, and we have shown that some AD risk variants, but not the NHD
mutant proteins are readily detected in the CSF of patients (Piccio et al., 2016). Because the AD
risk variant proteins are expressed and stable enough to be soluble factors, they may retain some
signaling ability and prevent more serious diseases. These hypotheses will require animal knock-in
studies for full evaluation. Therefore, a comprehensive analysis of all TREM2 variants will be essential
to understanding TREM2 function in both neurodegenerative diseases and other inflammatory diseases, and to design targeted therapies accordingly.

Materials and methods
Expression constructs
Full-length wild-type (WT) human TREM2 as well as R47H, N68K, D87N, and T96K mutants in pMX3p plasmid and mouse Trem2 cDNA were used as PCR templates. Mammalian cell expression constructs of human TREM2 wild-type, R47H, D87N, T96K and mouse TREM2 ectodomains were produced as previously described (Kober et al., 2014, 2015) by subcloning from these templates into
the pHLsec vector, which contains an optimized signal sequence and a C-terminal 6-histidine tag for
purification. Similarly, primers were designed to amplify the full-length human TREM2 gene with an
N-terminal FLAG peptide. Additional mutants (human Y38C, R62H, T66M, R76D, R77D; mouse
R47H, R62H, and T96K) were generated in the pHsec constructs using either the QuikChange Lightning Site-Direct Mutagenesis Kit (Agilent. Santa Clara, CA) or the Q5 Mutagenesis Kit (NEB) (primer
sequences in Table 3). WT and mutant human and mouse TREM2 constructs containing site-specific
biotinylation sites were generated by EcoRI-KpnI restriction digest of the pHLsec inserts followed by
ligation into the pHLAvitag3 vector, which encodes a C-terminal BirA biotin ligase biotinylation
sequence followed by a 6-histidine tag. All constructs were verified by sequencing.

Crystallization, structure determination, and analysis
The WT human TREM2 ectodomain was expressed in Freestyle 293F cells in the presence of 1 mg
mL 1 kifunensine, deglycosylated with EndoHf, and purified for crystallization in a single-step using
Ni-NTA resin as previously described (Kober et al., 2014). Protein was concentrated to 10 mg ml 1
in buffer containing 20 mM HEPES pH 7.4 and 150 mM NaCl. Crystals were grown by hanging drop
vapor diffusion by mixing 1:1 with well solution containing 100 mM HEPES 7.0, 2.1 M NaCl, 0.2 M
MgCl2 and 0.2 M NDSB-201. Crystals were cryoprotected in mother liquor containing 20% ethylene
glycol and flash frozen under a nitrogen stream at 160˚C.
Data were collected at the Advanced Photon Source, beamline 19-ID (Argonne National Lab, Chicago). A molecular replacement solution was found with PHASER using mouse TREM-1 ectodomain
(1 U9K) (Kelker et al., 2004a) as the probe, locating two molecules in the asymmetric unit (ASU).
Data were initially scaled and processed at 3.3 Å using HKL2000 (Otwinowski and Minor, 1997).
The initial model was substantially improved by iterative rounds of manual rebuilding in COOT
(Emsley et al., 2010) and refinement using Phenix (Adams et al., 2010). Next, resolution was
extended using the method described by Karplus and Diederichs (Karplus and Diederichs, 2012)
(Table 1). The 3.3 Å model was used as a molecular replacement probe on data scaled to 3.4 Å and
3.3 Å, and subsequently subjected to automated refinement in Phenix without manual intervention.
The 3.3 Å solution was then used to calculate Rfree and Rwork at 3.4 Å. Rfree was lower at 3.4 Å
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Table 3. Primers used in this study.
hTREM2
ectodomain

GAAACCGGTCACAACACCACAGTGTTCCAGGGC
CGGGGTACCCAGGGGGTCTGCCAGCACCTCCAC

hTREM2
Y38C*

CTGCAGGTGTCTTGCCCCTGTGACTCCATGAAGCACT
AGTGCTTCATGGAGTCACAGGGGCAAGACACTTGCAG

hTREM2
T66M*

TGCCAGCGTGTGGTCAGCATGCACAACTTGTGGCTGC
GCAGCCACAAGTTGTGCATGCTGACCACACGCTGGCA

hTREM2
V126G*

TCAGGAAGGTCCTGGGGGAGGTGCTGGCAGA
TCTGCCAGCACCTCCCCCAGGACCTTCCTGA

hTREM2
R62H+

CCCAGTCCAGCATGTGGTCAGCA
CCCTTCTCTCCCAGCTGGC

hTREM2
R76D+

GTCCTTCCTGGACAGGTGGAATGGG
AGCAGCCACAAGTTGTGC

hTREM2
R77D+

CTTCCTGAGGGACTGGAATGGGAGCACAG
GACAGCAGCCACAAGTTG

FLAG-hTREM2

GAAACCGGTGATTATAAAGATGATGATGATAAACACAACACCACAGTGTTCCAGGGC
CGGGGTACCTCACGTGTCTCTCAGCCCTGGCAG

mTREM2 ectodomain

GAAACCGGTCTCAACACCACGGTGCT
CGGGGTACCTTGGTCATCTAGAGGGT

mTREM2
R62H+

CCCATGCCAGCATGTGGTGAGCA
CCCTCCTCACCCAGCTGC

mTREM2
R47H*

AAGCACTGGGGGAGACACAAGGCCTGGTGTCGG
CCGACACCAGGCCTTGTGTCTCCCCCAGTGCTT

mTREM2
T96K*

CTTGCTGGAACCGTCACCATCAAGCTGAAGAACCTCCAAGCCGGT
ACCGGCTTGGAGGTTCTTCAGCTTGATGGTGACGGTTCCAGCAAG

mDAP12

CCGGAATTCGCCACCATGGGGGCTCTGGAGCCCTCCTGG
CGGGGTACCTCATCTGTAATATTGCCTCTGTGT

All primers 5’ 3’ with the coding direction primer listed first
*Designed for Quikchange Lightning Mutagenesis
Designed for NEB Q5 mutagenesis

+

DOI: 10.7554/eLife.20391.019

using the model refined at 3.3 Å compared to the model refined at 3.4 Å, providing evidence that
3.3 Å data improved the model. Similarly, data were again extended to 3.2 Å and finally 3.1 Å. Data
past 3.1 Å did not improve the model as determined by an increased Rfree calculated at 3.1 Å using
the model refined on 3.0 Å data. Final model refinement occurred by iterative building and refinement in Phenix. NCS and secondary structure restraints were used during refinement, and TLS
refinement of B-factors was applied in later rounds. The structure is complete with only one N-terminal residue and four C-terminal residues not visible in the electron density (Figure 1b). Ramachandran statistics are 97.7% favored, 0% outliers, 2.3% allowed. Molprobity score was 1.66 (100th
percentile) and clashscore was 9.62 (96th percentile) for the final model.
Calculations on the final model were performed using Naccess (Hubbard and Thornton, 1993) to
measure the solvent accessibility of side chains and HBPLUS (McDonald and Thornton, 1994) to
identify hydrogen bonds. LigPlot+ (Laskowski and Swindells, 2011) was used to analyze side-chain
contacts. For structure-based alignment, amino acid sequences were aligned using Clustal Omega
(Sievers et al., 2011) and residue conservation scored by ESPript (Robert and Gouet, 2014). All
crystallographic and analysis software used were compiled and distributed by the SBGrid resource
(Morin et al., 2013) and diffraction images were archived with the SB Data Grid (Meyer et al.,
2016).

Cell culture
For protein expression, Freestyle 293F cells were cultured at 8% CO2 in serum-free 293Freestyle
media supplemented with Glutamax and penicillin/streptomycin (Pen/Strep, Gibco by ThermoFisher,
Waltham, MA). Human monocyte THP-1 cells were cultured at 5% CO2 in RPMI media supplemented
with 10% Fetal Bovine Serum (FBS), 10 mM HEPES, 50 mM b-mercaptoethanol, L-glutamine and
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penicillin/streptomycin (Pen/Strep). Mouse neuroblast N2A cells were cultured at 5% CO2 in MEM
supplemented with 10% FBS, L-glutamine and Pen/Strep. CHO cells were cultured at 5% CO2 in
Ham’s F12 supplemented with 10% FBS, L-glutamine and Pen/Strep.

Protein expression and purification
Protein expression for biophysical and functional studies was performed as described previously
(Kober et al., 2014). In brief, plasmid DNA was complexed at a ratio of 1:2 (mg/mg) with PEI-TMC25
to transfect Freestyle 293F suspension cells cultured in serum-free 293 Freestyle Media. One mg of
plasmid DNA was used per 1  106 cells. Transfected cells were allowed to express protein for 72–
96 hr. Supernatants were collected and protein was purified using Ni-NTA chromatography. The
eluted protein was then further purified by gel filtration chromatography using an analytical s200
size-exclusion column (GE) run in a buffer containing 20 mM Tris pH 8.5 and 150 mM NaCl.

Surface expression studies
Full-length FLAG-tagged hTREM2 WT or mutant genes in pHL vectors were co-transfected with
mDAP12 in pcDNA3.1 vector into 293F cells using 293fectin. After 24 hr, cells were harvested and
washed into FACs buffer (1% BSA in PBS). FLAG epitope expression was detected using a FITC-conjugated M2 anti-FLAG antibody (1:50, Sigma-Aldrich. St. Louis, MO), and folded TREM2 surface
expression was detected by staining with anti-TREM2 primary polysera (1:1000, hamster) followed
by PE-anti-hamster secondary (1:200 eBioscience). Background was defined by cells transfected with
mouse DAP12 only.

WT and mutant TREM2 cell-surface ligand binding studies
Production of fluorescently labeled TREM2 tetramers
For analysis of cell binding by flow cytometry, pHLAvitag3 constructs of WT and mutant human and
mouse TREM2 ectodomains were transfected into Freestyle 293F cells and proteins were purified by
Ni-NTA chromatography. The eluted proteins were exchanged into buffer containing 100 mM TrisHCl pH 7.5, 200 mM K-glutamate, and 5 mM MgCl2, concentrated to 400 mL, and then enzymatic
biotinylation was carried out by addition of 40 mM bicine pH 8.3, 8 mM Mg(OAc)2, 8 mM ATP, 0.1
mM biotin and 20 mL Escherichia coli BirA biotin ligase (1 mg/mL). Biotinylation proceeded for 12 hr
at 4˚C. Excess biotin was removed using Zeba desalting spin columns (Thermo Scientific) and biotinylation was confirmed by western blot with Extravidin-HRP (Sigma). The biotinylated TREM2 was preincubated with SA-PE at a 4:1 molar ratio for 15 min at 25˚C to produce fluorescently labeled tetramers (TREM2/SA-PE). Biotinylated TREM2 was complexed with phycoerythrin-conjugated streptavidin (SA-PE) at a 4:1 molar ratio on ice for 1 hr in 1% FBS prior to staining cells.

Cell staining
Prior to staining, N2A and CHO cells were lifted following brief exposure to trypsin/EDTA (other
cells grow in suspension). Cells (4  105 cells/ sample) were stained using tetramers at 1:100 dilution
in PBS containing 1% FCS (FACS buffer) at 4˚C. Cells were either stained with SA-PE alone (1:100) or
with TREM2/SA-PE (1:100). Cells were incubated for 1 hr on ice then washed three times with FACS
buffer, and then analyzed for binding by flow cytometry using a BD FACScan. Analysis was performed using FlowJo (Tree Star).

Chemical stimulation
For each condition, 1 x 106 THP-1 cells were stimulated overnight at the indicated concentration.
Poly IC (1 mg mL 1), LPS (1 mg mL 1), PMA+ionomycin (20 ng mL 1 and 500 ng mL 1, respectively),
M-CSF (20 ng mL 1), and IL-13 (50 ng mL 1). Cells were collected and washed in FACs buffer before
staining.

Protease treatment
Cells were washed in ice-cold PBS and then incubated with indicated proteases (50 mg mL 1) on ice
for 30 min. Proteolysis was quenched by washing cells four times in FACs buffer containing PMSF.
Cells were stained with SAPE-TREM2 in FACs buffer containing PMSF and HALT protease inhibitors.
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Cell viability was verified by 7-AAD staining (BD Biosciences. San Jose, CA ) according to the manufacturer’s directions.

6-His staining of THP-1 cells
WT and mutant human TREM2 ectodomains were purified by SEC as in Figure 2—figure supplement 1. The monomeric peak was collected, concentrated and buffer-exchanged into PBS by centrifugation. Protein concentration was quantitated in triplicate using the Micro BCA kit (Thermo
Scientific) according to the manufacturer’s instructions. THP-1 cells were washed into FACS buffer
and incubated with purified proteins for 1 hr, washed twice, and then incubated in FACS media with
Fc-block followed by anti-6His-PE (Miltenyi Biotec. Germany) for 30 min before a final wash and flow
cytometry analysis. 20,000 cells were counted for each measurement.

Proteoglycan digestion assay
Chondroitinase ABC and Heparinases I, II, and III were purchased from Sigma-Aldrich. Digestion of
cell-surface sulfated glycans was carried out as follows: cells were washed into PBS with 0.1% BSA
and incubated with enzymes at 0.1 U mL 1 for 1 hr at 37˚C while shaking before being washed three
times with cold FACS buffer.

Thermostability of TREM2 variants by DSF
Thermal stability was assessed by differential scanning fluorimetry (DSF) on protein purified by SEC.
The Protein Thermal Shift kit (Applied Biosystems) was used according to the manufacturer’s instructions. Briefly, protein was concentrated to 0.5 mg mL 1 after buffer exchange into PBS. 5 ml of reaction buffer and 2.5 ml 8x fluorescent dye were added to 12.5 mL protein on ice. Melt-curve
experiments were performed using Fast7500 qPCR machine (ABI) starting at 25˚C and
with continuous 1% ramp to 95˚C (roughly 1˚C min 1). The data were analyzed using Protein Thermal
Shift software.

Thermal and chemical stability of TREM2 variants by CD
Circular dichroism spectroscopy (CD) measurements were performed using a JASCO J-815 spectropolarimeter equipped with a Peltier temperature controller. Thermal denaturation experiments were
carried out in 10 mM phosphate (pH 7.0) and 150 mM NaF. For native and GuHCl-denaturation
scans, a 1 mm path length cuvette was used and the protein concentration was 30 mM. For denaturation experiments, a 1 cm path length cuvette was used and the protein concentration was 3 mM.
For reducing conditions, the buffer contained 1 mM DTT. Ellipticity was measured at 225 nm in 1˚C
steps from 20˚C to 90˚C at a rate of 1˚C min 1 and melt-curve data were smoothed using JASCO
software. For chemical stability experiments, purified human ectodomains were incubated with
GuHCl (Fluka 50933) at room temperature for at least 1 hr before measuring CD. Repeat measurements at later time points confirmed that equilibrium had been achieved.

Solid-Phase lipid ELISA
Lipid ELISA experiments were carried out essentially as described by Kobayashi et al., (2007). In
brief, phospholipids were dissolved in methanol or methanol:chloroform as needed and diluted to 5
mg mL 1 in methanol. 100 mL was added to ELISA plates and allowed to air-dry. Wells were blocked
with 3% BSA in PBS. Biotinylated WT or mutant TREM2 in 3% BSA-PBS were incubated overnight at
4˚C. Plates were washed three times in PBS + 0.05% Tween 20. Biotinylated TREM2 was detected
by streptavidin-HRP (R and D) in 1% BSA-PBS for 2 hr at RT before final wash and developing with
TMB Microwell Peroxidase Substrate (KPL. Gaithersburg, MD). Absorbance was measured at 450 nm
on a Gemini Plus plate reader (Molecular Devices. Sunnyvale, CA).

Immunoflourescent confocal microscopy
HEK293T cells were co-transfected with full-length FLAG-TREM2 and DAP12 for 24 hr before replating on glass slides. Cells were washed 2x with PBS, then fixed with 4% paraformaldehyde (PFA) in
PBS for 5 min. Cells were then washed and blocked with animal-free blocker (Vector
Laboratories. Burlingame, CA) for 1 hr at RT. For permeabilized cells, 0.1% triton x-100 was added
to the blocking buffer and subsequent steps. Anti-FLAG antibody (M2, Sigma) was added at 1:1000
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overnight at 4˚C. Cells were then washed twice, and anti-mouse secondary Alexa Fluor 555 conjugate (Life Technologies) was added at 1:200 for 1 hr. Cells were washed a final time and then
mounted in VECTASHIELD H-1200 Mounting Medium with DAPI (Vector Laboratories). Confocal
microscopy was carried out using a Zeiss LSM 510 META Confocal Laser Scanning Microscope (Carl
Zeiss Microscopy, Thornwood, NY) at 400x magnification. The images were acquired with LSM 4.2
software.

Liposome sedimentation assays
Liposomes consisted of a base of 35:35:10 PtdCholine, PtdEthanolamine, and cholesterol with an
additional 20% wt/wt of candidate phospholipids. Phospholipids were purchased from Sigma or
Avanti dissolved in chloroform. Lipids were mixed in solvent-washed glass vials and solvent was
evaporated under nitrogen stream. Lipids were resuspended in PBS, warmed at 37˚C for 15 min followed by three freeze-thaw cycles on liquid N2 and 37˚C H2O. For the sedimentation assay, 10 mg
TREM2 proteins quantified by BCA were mixed with 100 mg liposomes and incubated for 1 hr at
room temperature. Liposomes were sedimented by centrifugation at 16,800 x g at 4˚C. The supernatant was removed and the pellet resuspended in SDS buffer for 6His immunoblot analysis.

Statistics
All statistics were calculated using GraphPad Prism5.
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